A Single-Dose Study to Evaluate the Effects of ABX-1431 on Gastric Accommodation and Nutrient Volume Tolerance in Patients With Functional Dyspepsia

Trial Profile

A Single-Dose Study to Evaluate the Effects of ABX-1431 on Gastric Accommodation and Nutrient Volume Tolerance in Patients With Functional Dyspepsia

Discontinued
Phase of Trial: Phase I

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs ABX 1431 (Primary)
  • Indications Non-ulcer dyspepsia
  • Focus Pharmacodynamics
  • Sponsors Abide Therapeutics
  • Most Recent Events

    • 05 Sep 2017 Status changed from recruiting to discontinued.
    • 14 Dec 2016 According to an Abide Therapeutics media release, dosing has commenced in this trial.
    • 22 Nov 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top